Rubophen Thermo

Quick links to important sections

Rubophen Thermo

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rubophen Thermo

Quick Facts

Property Description
Active Ingredients Acetaminophen, Phenylephrine Hydrochloride
Form Oral powder for solution
Pharmacological Class Analgesic, Antipyretic, Decongestant
Common Use Symptomatic relief of cold and flu
Origin Synthetic compound preparation

What Type of Medicine is Rubophen Thermo?

Rubophen Thermo is an Over-The-Counter (OTC) combination medicine specifically formulated for the symptomatic relief of common cold and flu discomfort. It belongs to the high-level pharmacological class of an Analgesic, Antipyretic, and Decongestant. The therapeutic strategy of combining these active ingredients to manage multiple viral upper respiratory symptoms is clinically recognized and supported by pharmacological studies. This approach confirms that combining these components is an established method to tackle several cold symptoms at once. The drug is prepared using synthetic compounds and is generally focused on the adult patient group.

Composition and Form: What are the Active Ingredients?

The preparation contains two principal active ingredients: Acetaminophen (often known as Paracetamol) and Phenylephrine Hydrochloride. Acetaminophen works as the pain reliever and fever reducer, while Phenylephrine Hydrochloride acts as the nasal decongestant. Rubophen Thermo is distinctively supplied in the dosage form of an oral powder for solution (or granules), intended to be mixed into a hot beverage. This oral route of administration provides systemic relief and offers a practical alternative to tablets, often with added soothing flavorings.

General Purpose: How Does Rubophen Thermo Help You Feel Better?

The general purpose of Rubophen Thermo is to increase comfort during illness by tackling two main areas of discomfort simultaneously. The Acetaminophen component works to help lower an elevated body temperature and ease general body aches and headaches. Concurrently, the Phenylephrine component constricts the blood vessels in the nasal passages, helping to relieve a blocked or stuffy nose. This established dual-action approach contributes significantly to overall patient comfort by providing both internal and respiratory relief.

What side effects are possible with Rubophen Thermo?

Possible Side Effects and Safety Information

The primary active ingredient in Rubophen Thermo is associated with risks of serious reactions when misused or, in rare cases, when used appropriately. Safety information from regulatory agencies emphasizes two key areas of risk: severe liver damage and serious skin reactions.


Clinically Significant Adverse Reactions

System-Organ Class Serious Adverse Reactions Frequency Classification
Hepatobiliary Severe liver damage and failure (potentially fatal), often linked to incorrect use or overdose. Dose-related; Very common with overdose.
Skin and Immune System Severe skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis), which can be fatal. Rare (occurs in less than 1 in 1,000 users)

Population and Use-Related Safety Warnings

  • Dose-Related Hepatotoxicity: Severe and potentially fatal liver damage is the most critical risk associated with the active component. This risk is primarily linked to exceeding the maximum recommended daily amount, using multiple products containing the same ingredient simultaneously, or chronic use with regular alcohol consumption.
  • Hypersensitivity: The possibility of rare but serious allergic reactions (e.g., swelling of the face, throat, or tongue; difficulty breathing) and skin reactions requires immediate discontinuation and medical attention if symptoms such as reddening of the skin, blisters, or rash develop.
  • Pediatric Safety: For use in children, official documents place emphasis on the critical need for precise adherence to weight- or age-based dosing guidelines and the use of the appropriate measuring device to prevent accidental overdose.

The regulatory safety profile mandates that all users be aware of the risk of liver damage and the signs of rare severe skin and allergic reactions.

Overdose and Emergency Response

Overdose Manifestations and Emergency Action

Overdose of combination products containing Acetaminophen and Phenylephrine is considered a potentially life-threatening event that requires immediate, non-negotiable medical attention. This is due to the delayed onset of severe toxicity, primarily from the Acetaminophen component.

Feature Official Regulatory Statements
Documented Manifestations Initial symptoms of Acetaminophen toxicity may include nausea, vomiting, diaphoresis (sweating), and general malaise. Severe overexposure to Phenylephrine can present with headache, palpitations, vomiting, or extreme blood pressure elevation.
Severe Outcomes Overdose can lead to fulminant hepatic necrosis and coma from Acetaminophen, or hypertensive crisis and potential cerebral hemorrhage from Phenylephrine.
Immediate Action Required Seek immediate medical attention or contact emergency services immediately (e.g., a poison control center). This action is mandated even if the person appears well and symptoms have not yet developed.
Antidote/Management A specific antidote, N-acetylcysteine, is documented to be available for Acetaminophen toxicity, with prompt administration being essential. Hospital monitoring is required, including the assessment of plasma Acetaminophen concentration and liver function tests.
Population Notes Increased risk of severe hepatic damage is noted in patients with pre-existing hepatic impairment and requires prompt attention for pediatric patients.

The official overdose profile is defined by the high risk of delayed, severe hepatic damage and the need for urgent antidote administration, which dictates the strict requirement to seek immediate medical attention upon any known or suspected overexposure.

Therapeutic Uses of Rubophen Thermo

What Rubophen Thermo treats: Main Uses and Benefits

Rubophen Thermo is generally used for the symptomatic management of discomfort arising from conditions associated with acute or disruptive episodes, specifically the common cold and influenza. The combination of active ingredients provides supportive relief by targeting the most pronounced symptom clusters that create noticeable physiological strain and interfere with daily stability. The components are used to address systemic and respiratory manifestations concurrently.

It is commonly used to help with a brief listing of indications including minor aches and pains, headache, fever, sore throat pain, and nasal or sinus congestion. This action assists with maintaining functional stability and contributes to improved day-to-day comfort during symptomatic periods.

Therapeutic Focus and Benefit

This medication is applied across therapeutic domains involving symptoms related to systemic imbalance (pain, fever) and upper respiratory discomfort (congestion). By being commonly used to help with pain relief and fever reduction, the medicine supports patients during difficult episodes by easing distress and contributes to easing the overall symptom load.

“This supportive relief is relevant for easing symptoms that create noticeable physiological strain.”

Quick Fact: Relief Focus Description
Systemic Symptoms Easing minor aches, pains, and reducing fever.
Respiratory Symptoms Addressing a stuffy nose and eases sinus pressure discomfort.

Regulatory References

  1. Acetaminophen/Phenylephrine Indications

Eligibility and Restrictions for Use

Eligibility Scope

The eligibility profile for Rubophen Thermo, based on official regulatory labeling, defines populations who are permitted, restricted, or prohibited from using the medicine.

Populations for whom use is allowed (as stated in label):

  • Adults and adolescents over the specified minimum age (typically 12 years or older) who do not have any listed contraindications or restrictions.

Populations for whom use is contraindicated:

  • Individuals with known hypersensitivity to the active ingredients (Acetaminophen or Phenylephrine).
  • Patients with severe heart disease (including severe hypertension or angina) or severe hepatic impairment (severe liver disease).
  • Patients with hyperthyroidism, phaeochromocytoma, or closed-angle glaucoma.
  • Individuals concurrently using, or having used within the last two weeks, a Monoamine Oxidase Inhibitor (MAOI).

Age-related eligibility rules:

  • The medicine is not recommended for use in children under the minimum age threshold established by the specific product license (often le 12 years).

Pregnancy and lactation eligibility status (if explicitly documented):

  • The medicine is generally not recommended for use during pregnancy or while breastfeeding.

Eligibility-related restrictions:

  • Use is advised with caution for patients with non-severe hepatic dysfunction, prostatic hypertrophy, or certain vascular conditions like Raynaud's phenomenon.

Connection to the overall eligibility profile

Regulatory documents establish absolute contraindications that prohibit use for individuals with severe pre-existing chronic conditions, such as advanced liver disease or certain heart disorders. Use is further limited by age-group restrictions that exclude younger children, and by physiological states such as pregnancy and lactation, for which use is officially not recommended.

What should I know about interactions with other medicines?

️ Absolute Contraindications and Restrictions

The regulatory profile mandates strict restrictions on co-administration. Use is formally prohibited with Monoamine Oxidase Inhibitors (MAOIs) due to the high risk of a hypertensive crisis. A non-negotiable separation of 14 days must pass after discontinuing MAOI therapy before taking this product. Co-administration with any other medicine containing Acetaminophen is also restricted across all prescription and non-prescription categories to prevent exceeding the maximum daily dose and risking severe liver damage.

Pharmacodynamic and Exposure Interactions

Official documentation notes key interactions that modify drug levels or effects:

Interaction Type Interacting Substance/Class Documented Outcome
Pharmacodynamic Sympathomimetic Agents, TCAs Additive pressor effects (hypertension risk)
Exposure-Modifying Warfarin Enhanced anticoagulant effect with prolonged use
Pharmacokinetic Acetaminophen Increased bioavailability of Phenylephrine component

The Phenylephrine component may also reduce the efficacy of antihypertensive agents like beta-blockers and methyldopa.

Substance-Specific Cautions

Chronic consumption of alcohol (ethanol), particularly three or more drinks daily, significantly increases the documented risk of Acetaminophen-induced hepatotoxicity. These risks are noted to be greater in patient populations with pre-existing cardiovascular disease or alcoholic liver disease.

Mechanism of Action

Central Modulation of Prostaglandin Synthesis (Paracetamol)

The Paracetamol component primarily functions by acting as an inhibitor of the cyclooxygenase (COX) enzyme system located within the Central Nervous System (CNS), which encompasses the brain and spinal cord. This interaction suppresses the production of the signaling molecule prostaglandin E2 ( PGE2) in the hypothalamus. The resulting reduction in central PGE2 levels leads to the modulation of the central thermoregulatory set-point and contributes to the limitation of nociceptive signal propagation within central pathways.

Peripheral alpha1-Adrenergic Receptor Agonism (Phenylephrine)

The Phenylephrine component operates by stimulating alpha1-adrenergic receptors present on the smooth muscle cells lining the small blood vessels in the nasal mucosa. Activation of these receptors initiates an intracellular signaling cascade that triggers smooth muscle contraction, resulting in vasoconstriction (narrowing) of the affected vessels. This physiological adjustment modifies the local hemodynamic dynamics within the nasal tissue by reducing local blood flow and swelling.

Dosage and Administration Information

How to use Rubophen Thermo — Official Administration Guidelines

This map outlines the procedural instructions for using Rubophen Thermo.

Administration Scope

Instruction Detail
Route of administration Oral route only, following preparation as a solution.
Dosing schedule One sachet per dose for adults and adolescents 16 years and over. Maximum of 4 sachets ( 4000 mg Paracetamol) in 24 hours.
Timing in relation to meals (if applicable) Can be taken with or without food.
Preparation requirements (if applicable) Contents must be fully dissolved in a standard mug of hot, non-boiling water ( 250 ml), stirred, and then cooled.
Age-group administration rules Not recommended for children under 16 without advice. No special dosage modification for the elderly.
Missed-dose rules Not specified in general patient instructions; dosing is as-needed.
Special procedural conditions Minimum interval of 4 hours between doses. Use restricted to 3 consecutive days maximum.

Instruction Classifications (High-Level)

Classification Detail
Administration method type Oral
Frequency pattern As-needed (intermittent use), subject to 4-hour interval constraint.
Use-context constraints Short-term use only and restricted from concurrent use with other paracetamol or decongestant products.

Resulting Procedural Structure

Official step sequence:

  • Dissolve one sachet in hot, non-boiling water ( 250 ml).
  • Stir to dissolve and cool before oral consumption.
  • Repeat dose only if needed, ensuring at least 4 hours have passed.

Connection to the overall use protocol: These instructions define the medicine as a strictly short-term, as-needed oral solution for systemic delivery. The protocol manages dosing by setting clear minimum dose intervals, a maximum daily limit, and prohibiting co-administration with similar active ingredients.

Recent Clinical Evidence

Rubophen Thermo: Recent Clinical Evidence

This section summarizes the key findings from research exploring the effects of the combination of Paracetamol (an analgesic/antipyretic) and Phenylephrine (a decongestant) in individuals experiencing symptoms of the common cold or flu-like illness.


Primary Trial Findings

Clinical studies have investigated the effectiveness of fixed-dose combinations (FDC) containing these active compounds for multi-symptom relief. A randomized, double-blind, placebo-controlled trial evaluated 146 adults with moderate to severe flu-like syndrome. The primary outcome measure assessed the reduction in the total symptom score (TSS), which combines scores for symptoms such as headache, fever, nasal congestion, and body aches.

  • Symptom Reduction: Analysis of overall symptom scores showed a significantly greater reduction in the group receiving the FDC compared to the placebo group. This reduction was observed within the initial 48 to 72 hours of treatment.
  • Study Endpoints: Symptom relief was also measured by the reduction in the mean TSS score, with researchers noting a reduction from baseline to follow-up visits.

Supportive Evidence

Further research, including open-labeled, multi-centric studies, has also examined the fixed-dose combination in adult patients. These studies contribute to the evidence base on how the combination is utilized for symptomatic relief.

Active Ingredient Primary Action Studied
Paracetamol Analgesic (pain relief) and antipyretic (fever reduction)
Phenylephrine Decongestant (relief of nasal congestion)

Phenylephrine, as an oral decongestant, was studied for its action in causing vasoconstriction of small blood vessels in the nasal mucosa, an effect linked to the alleviation of nasal swelling and congestion. Paracetamol's action in pain and fever reduction is thought to relate to its effects on prostaglandin synthesis within the central nervous system.

Key Studies & References

  1. Symptomatic treatment of the common cold with a fixed-dose combination of paracetamol, chlorphenamine and phenylephrine: a randomized, placebo-controlled trial
  2. Paracetamol and phenylephrine granules in healthy volunteers. A pharmacokinetic study
  3. Fever - MSF Medical Guidelines (Used for Paracetamol and Fever context)

Frequently Asked Questions (FAQ)

Common questions about Rubophen Thermo (FAQ)

Q: Does Rubophen Thermo interact with common cold or flu medications?

A: Official warnings advise against using this medicine alongside other products for cold and flu symptoms, particularly those that are vasoconstrictors (a type of drug that narrows blood vessels for congestion relief). Patients are advised to check the ingredients of other medicines and avoid any containing paracetamol (acetaminophen) to prevent exceeding the maximum daily limit.


Q: Can people with high blood pressure use Rubophen Thermo?

A: According to official product information, the medicine is formally contraindicated, or prohibited, for individuals who have severe high blood pressure (severe hypertension) or severe heart disease. If a person has any other pre-existing heart condition, regulatory documents generally indicate that caution is needed.


Q: Is there any research on Rubophen Thermo's use in younger populations?

A: The medicine is not recommended for use in children under the minimum age threshold established by the specific product license. The clinical research evidence referenced in official documents typically focuses on the effectiveness and safety of the combination in adult patients.


Q: Is the onset of action different when taken with food?

A: Official administration guidelines state the medicine can be taken with or without food. Although having food in the stomach may slightly influence the rate at which the active ingredients are absorbed, the overall systemic effect begins relatively rapidly.


Q: Does Rubophen Thermo help with muscle soreness?

A: The Paracetamol component of the medicine is an analgesic, which means it is used for the symptomatic relief of pain. According to official product indications, this relief covers general body aches and muscular aches associated with cold and flu symptoms.


Q: Why do some people report feeling jittery after taking it?

A: The Phenylephrine component is classified as a sympathomimetic amine. Official documentation lists adverse effects such as nervousness, tremor, and psychomotor agitation (restlessness), which may be described by users as feeling 'jittery.'


Q: Is Rubophen Thermo suitable for people with a history of heart issues?

A: Official documents state that the medicine is contraindicated for individuals with severe heart disease. For patients with a history of other cardiovascular issues that are not classified as severe, regulatory documentation indicates that caution is needed.


Q: Can I take Rubophen Thermo with my regular allergy medication?

A: Official sources state that caution is needed regarding the co-administration of this medicine with others, including allergy medications. This is especially true if the allergy medicine contains vasoconstrictor agents (decongestants), as combining them may increase the risk of cardiovascular side effects.


Q: What types of pain is Rubophen Thermo typically used to manage?

A: According to the official product label, the medicine is indicated for the symptomatic relief of pain related to cold and flu symptoms. These types of discomfort primarily include headache, sore throat, and general body aches.


Q: Why is this medicine called 'Thermo'?

A: The product name may relate to the action of the antipyretic component (Paracetamol). Regulatory information describes this ingredient as one that acts on the body's central heat-regulating system (the hypothalamic thermoregulatory center) to help lower an elevated body temperature, or fever.


Q: Is Rubophen Thermo the same as regular Rubophen?

A: Rubophen Thermo is a fixed-dose combination medicine containing two active ingredients: Paracetamol for pain/fever and Phenylephrine for nasal congestion. This composition is intended for multi-symptom relief, distinguishing it from products that may contain only a single active ingredient.


Q: Is Rubophen Thermo an anti-inflammatory drug?

A: The Paracetamol component is classified by regulatory authorities as an analgesic (pain reliever) and an antipyretic (fever reducer). Unlike certain other classes of pain relievers, this medicine is not generally classified as a drug that targets peripheral inflammation.


Q: How quickly can I expect Rubophen Thermo to start working?

A: Studies on the active ingredients show that the pain-relieving component typically reaches its peak plasma levels within 15 to 20 minutes after consumption. The decongestant effect of Phenylephrine is also observed to begin within a similar timeframe following oral administration.


Q: How long does the effect of Rubophen Thermo usually last?

A: The official administration protocol indicates that a minimum interval of 4 hours is necessary between doses, which relates to the duration of the drug's effect. The half-life of the Paracetamol component, which is the time it takes for half of the drug to be eliminated from the body, is approximately 2 hours.


Q: Is it normal to feel drowsy after taking Rubophen Thermo?

A: While the active ingredients are not typically associated with high rates of sedation, somnolence (drowsiness) is documented as a possible adverse reaction in the official product labeling.


Q: Can Rubophen Thermo cause stomach upset?

A: Official product labeling documents that gastrointestinal disturbances are possible adverse reactions. These effects may include nausea, vomiting, and discomfort or pain in the upper abdomen.


Q: Is Rubophen Thermo safe to take if I am already taking a vitamin supplement?

A: Official drug documentation does not typically include interaction information for most common vitamin supplements. Health authorities generally recommend seeking guidance from a healthcare professional when considering combining the medicine with any other supplements or remedies.


Q: What is the function of the secondary ingredients in Rubophen Thermo?

A: Regulatory documents list all ingredients in the formulation, including the auxiliary (secondary) components. These components, which may include flavorings and coloring agents, serve roles related to preparation, taste, stability, and product appearance.


Q: Can I take Rubophen Thermo if I have kidney problems?

A: According to official regulatory documents, the medicine is formally contraindicated for individuals with severe renal impairment (severe kidney disease). The label indicates that caution is needed for patients who have non-severe or other types of kidney problems.


Q: Does Rubophen Thermo contain stimulants like caffeine?

A: The official formulation of Rubophen Thermo lists Acetaminophen and Phenylephrine as its active ingredients. Caffeine is not listed as an active component in this core formulation.


Q: Are there known interactions between Rubophen Thermo and herbal supplements?

A: Official documentation does not provide comprehensive interaction data for all herbal supplements. Health authorities state that caution and professional consultation are necessary, as combining the medicine with herbal remedies may carry risks, particularly related to liver function or blood clotting.


Q: What is the half-life of Rubophen Thermo?

A: The half-life of an active ingredient is the time it takes for half of the dose to be eliminated from the body. Regulatory documents state the half-life of the Paracetamol component is approximately 2 hours, and the Phenylephrine component ranges from 2 to 3 hours.


Q: Is Rubophen Thermo considered a high-risk medication?

A: The medicine is regulated as an Over-The-Counter (OTC) product, which is a common administrative safety classification. However, official safety information mandates clear warnings regarding the risk of severe liver damage if misuse occurs, such as exceeding the daily limit or combining with other products containing paracetamol.


Q: Does Rubophen Thermo affect sleep?

A: Official documentation lists sleep disturbance, or insomnia, as a possible adverse reaction. This may be linked to the Phenylephrine component, which has sympathomimetic actions. Some health warnings state that use of decongestants like Phenylephrine close to bedtime should be avoided.


Q: Can I drive or operate machinery after using Rubophen Thermo?

A: Official advice states that if a person experiences symptoms such as dizziness, sleep disturbance, or any change in mental state while using this medicine, driving or operating machinery should be avoided.


Q: What are the signs of a non-serious adverse event from Rubophen Thermo?

A: Official labeling documents a range of adverse events. Those that are typically considered non-serious may include headache, nervousness, or gastrointestinal disturbances such as nausea and stomach upset.


Q: Is Rubophen Thermo absorbed differently by different people?

A: Pharmacokinetic studies on the active ingredients indicate that there is high variability in how the drug is absorbed and processed by different individuals. This means that the maximum concentrations of the drug reached in the body can vary significantly from person to person.


Q: Is there a known 'ceiling effect' for Rubophen Thermo's pain relief?

A: The Paracetamol component of the medicine is known to have an analgesic ceiling effect. This means that doses above a certain level (often cited in regulatory reviews) do not typically result in greater pain relief but may increase the risk of adverse effects.


Q: What are the primary safety classifications given to Rubophen Thermo?

A: The medicine is generally classified by regulatory authorities as an Over-The-Counter (OTC) product. This classification is an administrative safety measure indicating its availability without a prescription, subject to local regulations regarding specific pack-size and strength limitations.

How should Rubophen Thermo be stored and disposed of?

The storage and disposal of Rubophen Thermo must strictly adhere to the requirements specified in its official regulatory labeling to ensure product integrity and public safety.

Storage Conditions

  • The product must be stored at a temperature below 25, C.
  • It must be kept in the original package to ensure protection from light.
  • The medicine must be stored out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

  • Unused or expired medicinal products and waste material must be disposed of in accordance with local requirements.
  • The product must not be disposed of via household waste or wastewater.
  • Patients are officially advised to return any unused medicinal product to the pharmacist for regulated disposal.

These rules are mandated by regulatory authorities to maintain the product's stability and prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Rubophen Thermo found in:

A-Z Index: